Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CARDINAL HEALTH, INC.

(CAH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Cardinal Health : trade; Nuclear & Precision Health Solutions and IRE ELiT support the growing demand for Ga-68 labeled radiopharmaceuticals

08/27/2021 | 10:42am EDT
Cardinal Health™ Nuclear & Precision Health Solutions and IRE ELiT support the growing demand for Ga-68 labeled radiopharmaceuticals
08/27/2021
IRE ELiT submitted Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for the 100 mCi Ge68/Ga68 Galli Eo® generator.

DUBLIN, OHIO and FLEURUS, BELGIUM - AUGUST 26, 2021 - Cardinal Health (NYSE: CAH) and IRE ELiT (the radiopharmaceutical subsidiary of IRE Group) are working to expand patient access to novel radiopharmaceuticals for Positron Emission Tomography (PET) imaging as demand in the United States (U.S.) continues to grow. Cardinal Health is the preferred U.S. distributor of the IRE ELiT 100 mCi Germanium-68/Gallium-68 radionuclide generator (Ge-68/Ga-68 Galli Eo® generator) in support of clinical investigational trials, pre-commercial research and post-approval commercial sales in the U.S. and its territories, including Puerto Rico.

Designed for the on-site preparation of Ga-68 radiolabeled pharmaceuticals, IRE ELiT modified its Ge-68/Ga-68 Galli Eo® generator to double its activity from 50 mCi to 100 mCi. This activity enhancement will enable the Nuclear & Precision Health Solutions business of Cardinal Health to increase preparation of Ga-68 radiolabeled pharmaceuticals, which are approved and under investigation for many cancers.

The new, higher-activity 100 mCi generator provides users with more flexibility by increasing the number of daily elutions and the activity in each elution, ultimately increasing the number of patients that can be served. 'As a leading U.S. provider of Ga-68 radiopharmaceuticals, Cardinal Health commends IRE ELiT for their efforts to increase the activity of Ge-68/Ga-68 Galli Eo® generators,' said Mike Pintek, president of Cardinal Health™ Nuclear & Precision Health Solutions. 'Ultimately, this will allow us to better supply medical providers, and their patients, with current and future novel Ga-68 diagnostics.'

'Increasing the activity of our Galli Eo® generator is a critical part of our plan to meet the exponential demand for Ga-68 radiolabeled pharmaceuticals in the U.S.,' said Erich Kollegger, chief executive officer of IRE ELiT. 'Combining the expertise of our R&D department with the experience of our production team, IRE ELiT is prepared to produce and supply Cardinal Health with these high-activity generators.'

While the activity of the Ge-68/Ga-68 Galli Eo® generator has increased, the footprint of each unit will remain the same to ensure Cardinal Health can seamlessly transition to the new 100 mCi Ge-68/Ga-68 Galli Eo® generators without impact to the pharmacy.

Cardinal Health currently has the majority of its more than 130 nuclear pharmacies licensed for Gallium-68 and plans to license them all to expand patient access to PET imaging.

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 35 countries and approximately 44,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

Cardinal Health media contact:
Betsy Chaffee, betsy.chaffee@cardinalhealth.com and 614.757.6219

About IRE ELiT
IRE ELiT, the innovation subsidiary of the IRE, is a radiopharmaceutical company founded in 2010 to fully develop radiopharmaceuticals used in molecular imaging and therapy. IRE ELiT works closely with its clients in a «test & learn» spirit as well as with globally recognized universities and research centers. Today, IRE ELiT is one of only two global suppliers of germanium-68 (Ge-68)/gallium-68 (Ga-68) generators approved for use as a drug in Europe and as an active pharmaceutical ingredient (API) in the U.S. IRE and IRE ELiT currently employ 250 people. More information is available at www.ire.eu.

IRE media contact:
Bérénice Pignol, berenice.pignol@ire-elit.eu and (0032) 471 706 244

More Company News
08/27/2021

DUBLIN, OHIO and FLEURUS, BELGIUM - AUGUST 26, 2021 - Cardinal Health (NYSE: CAH) and IRE ELiT (the radiopharmaceutical subsidiary of IRE Group) are working to expand patient access to novel...

08/24/2021

By Ola Snow, Chief Human Resources Officer At Cardinal Health, diversity, equity and inclusion (DE&I) are business imperatives. We are deeply committed to creating a workplace where every employee...

08/23/2021

Cardinal Health (NYSE: CAH) announced today a comprehensive talent strategy to increase representation of diverse employees at the manager level and above by 2030. This commitment is specifically...

08/20/2021

DUBLIN, OHIO - August 20, 2021 - Cardinal Health (NYSE: CAH) issued a voluntary Medical Device correction notice on June 16, 2021 for Argyle™ UVC Insertion Tray containing Safety Scalpel...

View all company news »

* Required Fields
* First Name
* Last Name
* Email

Disclaimer

Cardinal Health Inc. published this content on 27 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 27 August 2021 14:41:04 UTC.


ę Publicnow 2021
All news about CARDINAL HEALTH, INC.
10/15HISPANIC PHARMACISTS : Advancing health equity
PU
10/14VIRTUAL INTERVIEWING DURING THE PAND : How to seek your next role with peace of mind
PU
10/14CARDINAL HEALTH : OptiFreight Logistics to Ship Journey Biosciences' Diabetes Screening Te..
MT
10/14CARDINAL HEALTH : Journey Biosciences and Cardinal Health OptiFreight« Logistics Collabora..
PR
10/14Journey Biosciences and Cardinal Health, Inc. Optifreight Logistics Collaborate to Impr..
CI
10/12Cardinal Health, Inc. Provides Business Solutions for the Next Public Health Emergency
CI
10/06CARDINAL HEALTH : New Cardinal Health survey explores how rheumatologists are managing cur..
PR
10/04WALGREENS BOOTS ALLIANCE : Pharmacy chains failed to prevent opioid misuse, U.S. jury hear..
RE
10/04U.S. Supreme Court rejects challenge to New York tax on opioid companies
RE
09/30ENDO INTERNATIONAL : California judge questions counties' opioid case against drugmakers a..
RE
More news
Analyst Recommendations on CARDINAL HEALTH, INC.
More recommendations
Financials (USD)
Sales 2022 172 B - -
Net income 2022 1 298 M - -
Net Debt 2022 1 300 M - -
P/E ratio 2022 10,9x
Yield 2022 4,12%
Capitalization 13 774 M 13 774 M -
EV / Sales 2022 0,09x
EV / Sales 2023 0,08x
Nbr of Employees 46 827
Free-Float 88,4%
Chart CARDINAL HEALTH, INC.
Duration : Period :
Cardinal Health, Inc. Technical Analysis Chart | CAH | US14149Y1082 | MarketScreener
Technical analysis trends CARDINAL HEALTH, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 48,54 $
Average target price 56,85 $
Spread / Average Target 17,1%
EPS Revisions
Managers and Directors
Michael C. Kaufmann Chief Executive Officer & Director
Jason M. Hollar Chief Financial Officer
Gregory B. Kenny Independent Non-Executive Chairman
Brian S. Rice Chief Information Officer & Executive VP
Jessica L. Mayer Chief Compliance & Legal Officer
Sector and Competitors